118 related articles for article (PubMed ID: 29157115)
1. Subgroup analysis based on prognostic and predictive gene signatures for adjuvant chemotherapy in early-stage non-small-cell lung cancer patients.
Moon H; Zhao Y; Pluta D; Ahn H
J Biopharm Stat; 2018; 28(4):750-762. PubMed ID: 29157115
[TBL] [Abstract][Full Text] [Related]
2. Genomic signatures for predicting survival and adjuvant chemotherapy benefit in patients with non-small-cell lung cancer.
Van Laar RK
BMC Med Genomics; 2012 Jul; 5():30. PubMed ID: 22748043
[TBL] [Abstract][Full Text] [Related]
3. Molecular prediction of adjuvant cisplatin efficacy in Non-Small Cell Lung Cancer (NSCLC)-validation in two independent cohorts.
Buhl IK; Santoni-Rugiu E; Ravn J; Hansen A; Christensen IJ; Jensen T; Pratt B; Askaa J; Jensen PB; Knudsen S; Sørensen JB
PLoS One; 2018; 13(3):e0194609. PubMed ID: 29566065
[TBL] [Abstract][Full Text] [Related]
4. A Cost-Effectiveness Analysis of Using the JBR.10-Based 15-Gene Expression Signature to Guide Adjuvant Chemotherapy in Early Stage Non-Small-Cell Lung Cancer.
Wong KM; Ding K; Li S; Bradbury P; Tsao MS; Der SD; Shepherd FA; Chung C; Ng R; Seymour L; Leighl NB
Clin Lung Cancer; 2017 Jan; 18(1):e41-e47. PubMed ID: 27502323
[TBL] [Abstract][Full Text] [Related]
5. Identification of Risk Factors and Likelihood of Benefit from Adjuvant Chemotherapy for Early Stage Lung Cancer Patients.
Moon H; Chao T; Ahn H
J Biopharm Stat; 2020 May; 30(3):430-444. PubMed ID: 31662030
[TBL] [Abstract][Full Text] [Related]
6. Predictive and prognostic effect of CD133 and cancer-testis antigens in stage Ib-IIIA non-small cell lung cancer.
Su C; Xu Y; Li X; Ren S; Zhao C; Hou L; Ye Z; Zhou C
Int J Clin Exp Pathol; 2015; 8(5):5509-18. PubMed ID: 26191258
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant Chemotherapy Guided by Molecular Profiling and Improved Outcomes in Early Stage, Non-Small-Cell Lung Cancer.
Woodard GA; Wang SX; Kratz JR; Zoon-Besselink CT; Chiang CY; Gubens MA; Jahan TM; Blakely CM; Jones KD; Mann MJ; Jablons DM
Clin Lung Cancer; 2018 Jan; 19(1):58-64. PubMed ID: 28645632
[TBL] [Abstract][Full Text] [Related]
8. Cancer adjuvant chemotherapy strategic classification by artificial neural network with gene expression data: An example for non-small cell lung cancer.
Chen YC; Chang YC; Ke WC; Chiu HW
J Biomed Inform; 2015 Aug; 56():1-7. PubMed ID: 25998519
[TBL] [Abstract][Full Text] [Related]
9. The coming of age of molecular tumor profiling.
Antonoff MB; D'Cunha J
Semin Thorac Cardiovasc Surg; 2011; 23(1):8-9. PubMed ID: 21807290
[TBL] [Abstract][Full Text] [Related]
10. Individualized adjuvant chemotherapy for surgically resected lung cancer and the roles of biomarkers.
Ikeda N; Nagase S; Ohira T
Ann Thorac Cardiovasc Surg; 2009 Jun; 15(3):144-9. PubMed ID: 19597387
[TBL] [Abstract][Full Text] [Related]
11. An extracellular matrix-related prognostic and predictive indicator for early-stage non-small cell lung cancer.
Lim SB; Tan SJ; Lim WT; Lim CT
Nat Commun; 2017 Nov; 8(1):1734. PubMed ID: 29170406
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.
Vansteenkiste JF; Cho BC; Vanakesa T; De Pas T; Zielinski M; Kim MS; Jassem J; Yoshimura M; Dahabreh J; Nakayama H; Havel L; Kondo H; Mitsudomi T; Zarogoulidis K; Gladkov OA; Udud K; Tada H; Hoffman H; Bugge A; Taylor P; Gonzalez EE; Liao ML; He J; Pujol JL; Louahed J; Debois M; Brichard V; Debruyne C; Therasse P; Altorki N
Lancet Oncol; 2016 Jun; 17(6):822-835. PubMed ID: 27132212
[TBL] [Abstract][Full Text] [Related]
13. [Adjuvant chemotherapy for resectable non-small cell lung cancer (NSCLC)].
Nakajima E; Katou H
Kyobu Geka; 2008 Jan; 61(1):4-8. PubMed ID: 18186265
[TBL] [Abstract][Full Text] [Related]
14. NCC-AUC: an AUC optimization method to identify multi-biomarker panel for cancer prognosis from genomic and clinical data.
Zou M; Liu Z; Zhang XS; Wang Y
Bioinformatics; 2015 Oct; 31(20):3330-8. PubMed ID: 26092859
[TBL] [Abstract][Full Text] [Related]
15. Prognostic and predictive markers of benefit from adjuvant chemotherapy in early-stage non-small cell lung cancer.
Custodio AB; González-Larriba JL; Bobokova J; Calles A; Alvarez R; Cuadrado E; Manzano A; Díaz-Rubio E
J Thorac Oncol; 2009 Jul; 4(7):891-910. PubMed ID: 19433989
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant chemotherapy for completely resected non-small-cell lung cancer.
Suehisa H; Toyooka S
Acta Med Okayama; 2009 Oct; 63(5):223-30. PubMed ID: 19893597
[TBL] [Abstract][Full Text] [Related]
17. MMS19 as a potential predictive marker of adjuvant chemotherapy benefit in resected non-small cell lung cancer.
Adam J; Sourisseau T; Olaussen KA; Robin A; Zhu CQ; Templier A; Civet A; Girard P; Lazar V; Validire P; Tsao MS; Soria JC; Besse B
Cancer Biomark; 2016 Sep; 17(3):323-333. PubMed ID: 27802208
[TBL] [Abstract][Full Text] [Related]
18. Circulating exosomal microRNAs as prognostic biomarkers for non-small-cell lung cancer.
Liu Q; Yu Z; Yuan S; Xie W; Li C; Hu Z; Xiang Y; Wu N; Wu L; Bai L; Li Y
Oncotarget; 2017 Feb; 8(8):13048-13058. PubMed ID: 28055956
[TBL] [Abstract][Full Text] [Related]
19. Patterns and Predictors of Chemotherapy Use for Resected Non-Small Cell Lung Cancer.
Rajaram R; Paruch JL; Mohanty S; Holl JL; Bilimoria KY; Ko CY; Winchester DP; Patel JD; DeCamp MM
Ann Thorac Surg; 2016 Feb; 101(2):533-40. PubMed ID: 26507427
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant cisplatin-based chemotherapy for resected NSCLC: one size fits all?
Geiger S; Schlemmer M; Heinemann V; Stemmler HJ
Anticancer Drugs; 2010 Oct; 21(9):799-804. PubMed ID: 20679887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
